Subscribe
eye-istock-489756064-mark_kuiken-
Mark_Kuiken / iStockphoto.com
20 March 2017Americas

Allergan to pay Editas $90m for development of CRISPR eye treatment

Allergan Pharmaceuticals and genome-editing company Editas Medicine have entered into a strategic research and development agreement over CRISPR technology.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
article
CRISPR specialist raises $80m in funding
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.


Editor's picks

Life sciences leaders recognised at LSPN Awards USA 2025
Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

Editor's picks

Americas
Life sciences leaders recognised at LSPN Awards USA 2025
8 May 2025

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
article
CRISPR specialist raises $80m in funding
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More on this story

Biotechnology
Japan’s IP office upholds CRISPR patent and allows third
1 June 2021   A CRISPR patent filed by scientist Emmanuelle Charpentier alongside the Regents of the University of California and the University of Vienna has been upheld by the Japan Patent Office.
article
CRISPR specialist raises $80m in funding
28 September 2018   US company KSQ Therapeutics, a specialist in using CRISPR for drug development, has raised $80 million in series C funding.

More features

Life sciences leaders recognised at LSPN Awards USA 2025
UK-India trade deal is ‘a missed opportunity for UK pharma’, says industry body
LSPN: Counsel grapple with AI’s impact on training and critical thinking
'Nothing can stand in the way of our work': Ukraine resumes IP system
LSPN: Trump's policy storm causing chaos and confusion
Taylor Wessing expands in Europe with Paris team
LSPN: Using ‘the patentee’s friend’ in Section 112 claims
ResMed voids sleep apnoea tech patent at PTAB